Allstate Corporation’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-4,701
| Closed | -$1.27M | – | 194 |
|
|
2025
Q1 | $1.27M | Buy |
4,701
+903
| +24% | +$244K | 0.04% | 285 |
|
|
2024
Q4 | $894K | Buy |
+3,798
| New | +$894K | 0.03% | 341 |
|
|
2023
Q1 | – | Sell |
-5,228
| Closed | -$1.24M | – | 221 |
|
|
2022
Q4 | $1.24M | Buy |
5,228
+78
| +2% | +$18.5K | 0.04% | 302 |
|
|
2022
Q3 | $1.03M | Buy |
5,150
+358
| +7% | +$71.7K | 0.03% | 329 |
|
|
2022
Q2 | $699K | Sell |
4,792
-3,285
| -41% | -$479K | 0.02% | 424 |
|
|
2022
Q1 | $1.32M | Sell |
8,077
-2,782
| -26% | -$454K | 0.04% | 341 |
|
|
2021
Q4 | $1.84M | Buy |
10,859
+5,490
| +102% | +$931K | 0.04% | 414 |
|
|
2021
Q3 | $1.01M | Sell |
5,369
-445
| -8% | -$84K | 0.04% | 282 |
|
|
2021
Q2 | $986K | Sell |
5,814
-375
| -6% | -$63.6K | 0.03% | 308 |
|
|
2021
Q1 | $874K | Buy |
6,189
+973
| +19% | +$137K | 0.03% | 355 |
|
|
2020
Q4 | $678K | Sell |
5,216
-286
| -5% | -$37.2K | 0.02% | 381 |
|
|
2020
Q3 | $801K | Sell |
5,502
-158
| -3% | -$23K | 0.03% | 287 |
|
|
2020
Q2 | $838K | Sell |
5,660
-1,068
| -16% | -$158K | 0.03% | 298 |
|
|
2020
Q1 | $732K | Sell |
6,728
-8,296
| -55% | -$903K | 0.03% | 277 |
|
|
2019
Q4 | $1.73M | Hold |
15,024
| – | – | 0.03% | 332 |
|
|
2019
Q3 | $1.21M | Buy |
15,024
+11,290
| +302% | +$908K | 0.02% | 367 |
|
|
2019
Q2 | $271K | Sell |
3,734
-3,106
| -45% | -$225K | ﹤0.01% | 461 |
|
|
2019
Q1 | $639K | Buy |
6,840
+33
| +0.5% | +$3.08K | 0.02% | 325 |
|
|
2018
Q4 | $496K | Buy |
+6,807
| New | +$496K | 0.02% | 327 |
|